AI Science Tracker
EN

Development of a Diagnostic Model for Focal Segmental Glomerulosclerosis: Integrating Machine Learning on Activated Pathways and Clinical Validation

The First Affiliated Hospital of Anhui Medical University; The Second People's Hospital of Hefei · 26 Feb 2025 · medicine

Discovery

Development of a Diagnostic Model for Focal Segmental Glomerulosclerosis: Integrating Machine Learning on Activated Pathways and Clinical Validation

Source check: Source checked. Not independent scientific confirmation.

Finding: Across 163 patients with focal segmental glomerulosclerosis and 42 living-donor controls in GEO cohorts, the glmBoost+Ridge model using six genes distinguished FSGS from controls. Its AUCs were 1.000, 0.994 and 1.000 across three development/validation cohorts and 0.910 and 0.775 in two platforms of the external cohort (overall AUC about 0.885). Immunohistochemistry supported elevated CD99 and OAZ2 expression. These retrospective expression-cohort results and small tissue validation do not establish clinical diagnostic utility.

Technology: glmBoost+Ridge

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
glmBoost+Ridge combines six gene-expression features (BANF1, TUSC2, SMAD3, TGFB1, CD99 and OAZ2) to classify focal segmental glomerulosclerosis.
Test and result
The glmBoost+Ridge six-gene FSGS model was tested across three GEO cohorts and an independent GEO cohort; internal AUCs were 1.000, 0.994 and 1.000, while the external cohort platform AUCs were 0.910 and 0.775 (combined about 0.885). Immunohistochemistry in 16 FSGS patients and 7 controls supported CD99/OAZ2 expression differences.
Limitation / still unknown
Near-perfect cohort AUCs may not generalize; the independent GEO platform results differed, and clinical diagnostic utility was not demonstrated.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11872063/ · https://europepmc.org/article/MED/40026806

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.